Julia Button1, Omar Al-Louzi1, Andrew Lang1, Pavan Bhargava1, Scott D Newsome1, Teresa Frohman1, Laura J Balcer1, Elliot M Frohman1, Jerry Prince1, Peter A Calabresi1, Shiv Saidha2. 1. From the Departments of Neurology (J.B., O.A.-L., P.B., S.D.N., P.A.C., S.S.) and Electrical and Computer Engineering (A.L., J.P.), Johns Hopkins University, Baltimore, MD; Department of Internal Medicine (O.A.-L.), North Shore Medical Center, Salem, MA; Department of Neurology and Ophthalmology (T.F., E.M.F.), University of Texas Southwestern, Dallas; and Department of Neurology (L.J.B.), New York University Langone Medical Center, New York. 2. From the Departments of Neurology (J.B., O.A.-L., P.B., S.D.N., P.A.C., S.S.) and Electrical and Computer Engineering (A.L., J.P.), Johns Hopkins University, Baltimore, MD; Department of Internal Medicine (O.A.-L.), North Shore Medical Center, Salem, MA; Department of Neurology and Ophthalmology (T.F., E.M.F.), University of Texas Southwestern, Dallas; and Department of Neurology (L.J.B.), New York University Langone Medical Center, New York. ssaidha2@jhmi.edu.
Abstract
OBJECTIVE: To retrospectively investigate whether disease-modifying therapies (DMTs) exert differential effects on rates of retinal atrophy in relapsing-remitting multiple sclerosis (RRMS), as assessed using optical coherence tomography (OCT). METHODS: A total of 402 patients with RRMS followed at the Johns Hopkins MS Center who underwent Cirrus-HD OCT were assessed for eligibility. Inclusion criteria included at least 1 year of OCT follow-up and adherence to a single DMT during the period of follow-up. Combined thickness of the ganglion cell + inner plexiform (GCIP) and other retinal layers was computed utilizing automated macular segmentation. Retinal thickness changes were analyzed using mixed-effects linear regression. RESULTS: The effects of glatiramer acetate (GA; n = 48), natalizumab (NAT; n = 46), and interferon-β-1a subcutaneously (IFNSC; n = 35) and intramuscularly (IFNIM; n = 28) were assessed. Baseline analyses revealed no significant differences between groups in terms of age, sex, optic neuritis history, or follow-up duration. During follow-up, relative to NAT-treated patients, IFNSC- and GA-treated patients exhibited 0.37 μm/y (p < 0.001) and 0.14 μm/y (p = 0.035) faster rates of GCIP thinning, respectively, adjusting for the interval between initiation of DMT and OCT monitoring (gap time), age, sex, relapses, and disease duration. In the IFNSC group, GCIP thinning was 1.53 μm/y faster during the first year of therapy vs during the time interval afterwards (p < 0.001). CONCLUSIONS: Rates of GCIP atrophy in patients with RRMS vary according to DMT utilization. Our findings support OCT for monitoring neurodegenerative treatment effects in the retina, an easily accessible tissue, and as a practical outcome measure in RRMS clinical trials.
OBJECTIVE: To retrospectively investigate whether disease-modifying therapies (DMTs) exert differential effects on rates of retinal atrophy in relapsing-remitting multiple sclerosis (RRMS), as assessed using optical coherence tomography (OCT). METHODS: A total of 402 patients with RRMS followed at the Johns Hopkins MS Center who underwent Cirrus-HD OCT were assessed for eligibility. Inclusion criteria included at least 1 year of OCT follow-up and adherence to a single DMT during the period of follow-up. Combined thickness of the ganglion cell + inner plexiform (GCIP) and other retinal layers was computed utilizing automated macular segmentation. Retinal thickness changes were analyzed using mixed-effects linear regression. RESULTS: The effects of glatiramer acetate (GA; n = 48), natalizumab (NAT; n = 46), and interferon-β-1a subcutaneously (IFNSC; n = 35) and intramuscularly (IFNIM; n = 28) were assessed. Baseline analyses revealed no significant differences between groups in terms of age, sex, optic neuritis history, or follow-up duration. During follow-up, relative to NAT-treated patients, IFNSC- and GA-treated patients exhibited 0.37 μm/y (p < 0.001) and 0.14 μm/y (p = 0.035) faster rates of GCIP thinning, respectively, adjusting for the interval between initiation of DMT and OCT monitoring (gap time), age, sex, relapses, and disease duration. In the IFNSC group, GCIP thinning was 1.53 μm/y faster during the first year of therapy vs during the time interval afterwards (p < 0.001). CONCLUSIONS: Rates of GCIP atrophy in patients with RRMS vary according to DMT utilization. Our findings support OCT for monitoring neurodegenerative treatment effects in the retina, an easily accessible tissue, and as a practical outcome measure in RRMS clinical trials.
Authors: J Sastre-Garriga; C Tur; D Pareto; A Vidal-Jordana; C Auger; J Río; E Huerga; M Tintoré; A Rovira; X Montalban Journal: Mult Scler Date: 2014-11-12 Impact factor: 6.312
Authors: Stephanie B Syc; Christina V Warner; Girish S Hiremath; Sheena K Farrell; John N Ratchford; Amy Conger; Teresa Frohman; Gary Cutter; Laura J Balcer; Elliot M Frohman; Peter A Calabresi Journal: Mult Scler Date: 2010-06-08 Impact factor: 6.312
Authors: Angela Vidal-Jordana; Jaume Sastre-Garriga; Francisco Pérez-Miralles; Carmen Tur; Mar Tintoré; Alejandro Horga; Cristina Auger; Jordi Río; Carlos Nos; Mari C Edo; María J Arévalo; Joaquín Castilló; Alex Rovira; Xavier Montalban Journal: Mult Scler Date: 2013-01-14 Impact factor: 6.312
Authors: Shiv Saidha; Stephanie B Syc; Mary K Durbin; Christopher Eckstein; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott Newsome; John N Ratchford; Elliot M Frohman; Peter A Calabresi Journal: Mult Scler Date: 2011-08-24 Impact factor: 6.312
Authors: H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: Veronica Popescu; Federica Agosta; Hanneke E Hulst; Ingrid C Sluimer; Dirk L Knol; Maria Pia Sormani; Christian Enzinger; Stefan Ropele; Julio Alonso; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban; Benedetta Bodini; Olga Ciccarelli; Zhaleh Khaleeli; Declan T Chard; Lucy Matthews; Jaqueline Palace; Antonio Giorgio; Nicola De Stefano; Philipp Eisele; Achim Gass; Chris H Polman; Bernard M J Uitdehaag; Maria Jose Messina; Giancarlo Comi; Massimo Filippi; Frederik Barkhof; Hugo Vrenken Journal: J Neurol Neurosurg Psychiatry Date: 2013-03-23 Impact factor: 10.154
Authors: Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag Journal: Lancet Neurol Date: 2008-09-11 Impact factor: 44.182
Authors: Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi Journal: Lancet Neurol Date: 2012-10-04 Impact factor: 44.182
Authors: Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi Journal: Brain Date: 2018-11-01 Impact factor: 13.501
Authors: Jiwon Oh; Daniel Ontaneda; Christina Azevedo; Eric C Klawiter; Martina Absinta; Douglas L Arnold; Rohit Bakshi; Peter A Calabresi; Ciprian Crainiceanu; Blake Dewey; Leorah Freeman; Susan Gauthier; Roland Henry; Mathilde Inglese; Shannon Kolind; David K B Li; Caterina Mainero; Ravi S Menon; Govind Nair; Sridar Narayanan; Flavia Nelson; Daniel Pelletier; Alexander Rauscher; William Rooney; Pascal Sati; Daniel Schwartz; Russell T Shinohara; Ian Tagge; Anthony Traboulsee; Yi Wang; Youngjin Yoo; Tarek Yousry; Yunyan Zhang; Nancy L Sicotte; Daniel S Reich Journal: Neurology Date: 2019-02-20 Impact factor: 9.910
Authors: Laura J Balcer; Lisanne J Balk; Alexander U Brandt; Peter A Calabresi; Elena H Martinez-Lapiscina; Rachel C Nolan; Friedemann Paul; Axel Petzold; Shiv Saidha Journal: J Neuroophthalmol Date: 2018-12 Impact factor: 3.042
Authors: Jeffrey Lambe; Hunter Risher; Angeliki G Filippatou; Olwen C Murphy; Elias S Sotirchos; Henrik Ehrhardt; Esther Ogbuokiri; Nicole Pellegrini; Brandon Toliver; Nicholas J Luciano; Simidele Davis; Nicholas Fioravante; Ohemaa Kwakyi; Jerry L Prince; Peter A Calabresi; Kathryn C Fitzgerald; Shiv Saidha Journal: Neurology Date: 2021-04-07 Impact factor: 9.910
Authors: Elias S Sotirchos; Natalia Gonzalez Caldito; Angeliki Filippatou; Kathryn C Fitzgerald; Olwen C Murphy; Jeffrey Lambe; James Nguyen; Julia Button; Esther Ogbuokiri; Ciprian M Crainiceanu; Jerry L Prince; Peter A Calabresi; Shiv Saidha Journal: Ann Neurol Date: 2020-04-28 Impact factor: 10.422